Studies Investigating Response-Adapted Therapy in NHL
| Results | ||||
| Study | Patient population | Methodology | PET+ | PET− |
| Moskowitz, 2006 (62) | 87 bulky/advanced-DLBCL patients | PET-4 (R-CHOP); PET− and PET+/biopsy− completed 3 cycles ICE; PET+/biopsy+ completed 3 cycles ICE, high-dose chemotherapy, ASCT | EFS: 87%* | EFS: 91%* |
| Kasamon, 2009 (63) | 59 patients (56 DLBCL, 10 primary mediastinal large B-cell lymphoma, 2 follicular lymphoma, 1 peripheral T-cell; 20 limited, 39 advanced) | PET-2 or PET-3; PET− completed standard therapy; PET+ escalated to salvage chemotherapy, ASCT | 2-y EFS: 67% | 2-y EFS: 89% |
| Moskowitz, 2010 (64) | 98 DLBCL patients (15 limited/bulky, 83 advanced) | PET-4 (R-CHOP); PET− and PET+/biopsy− completed 3 cycles ICE; PET+/biopsy+ completed 3 cycles ICE, high-dose chemotherapy, ASCT | PFS: 60% (biopsy+), 79% (biopsy−) | PFS: 86% |
| Swinnen, 2012 (65) | 78 bulky/advanced-DLBCL patients | PET-3 or PET-4 (R-CHOP); PET− completed 2 more cycles; PET+ escalated to 4 cycles R-ICE | 2-y PFS: 45% | 2-y PFS: 77% |
| Sehn, 2014 (66) | 155 DLBCL patients (50 limited, 105 advanced) | PET-4 (R-CHOP); PET− completed 2 more cycles; PET+ escalated to 4 cycles R-ICE | 4-y PFS: 59%; 4-y OS: 73% | 4-y PFS: 91%; 4-y OS: 96% |
| Swinnen, 2015 (67) | 80 DLBCL patients (8 limited, 72 advanced) | PET-3 or PET-4 (R-CHOP); PET− completed 2 more cycles; PET+ escalated to 4 cycles R-ICE | 2-y PFS: 42%; 3-y OS: 69% | 2-y PFS: 76%; 3-y OS: 93% |
↵* Nonsignificant.
ICE = ifosfamide, carboplatin, etoposide; EFS = event-free survival; R-ICE = rituximab, ifosfamide, carboplatin, and etoposide; OS = overall survival.